IgPro20
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Trial Timeline
Jul 30, 2014 → Jul 10, 2017
NCT ID
NCT02027701About IgPro20
IgPro20 is a phase 3 stage product being developed by CSL for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The current trial status is completed. This product is registered under clinical trial identifier NCT02027701. Target conditions include Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Polyradiculoneuropathy, Chronic Inflammatory Demyelinating.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03033745 | Approved | Completed |
| NCT02027701 | Phase 3 | Completed |
| NCT00751621 | Phase 3 | Completed |
| NCT00719680 | Phase 3 | Completed |
Competing Products
20 competing products in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| macitentan 10 mg | BML, Inc. | Phase 3 | 76 |
| KPL-716 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| TERN-701 | Terns Pharmaceuticals | Phase 1/2 | 38 |
| Fludarabine + Cyclophosphamide + PRGN-3007 | Precigen | Phase 1 | 28 |
| LY3556050 + Placebo | Eli Lilly | Phase 2 | 52 |
| THB001 | Third Harmonic Bio | Phase 1 | 25 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 2 | 44 |
| Empagliflozin + Matching placebo | Eli Lilly | Phase 3 | 77 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Venetoclax + Rituximab | Eli Lilly | Phase 3 | 77 |
| LY3526318 + Placebo | Eli Lilly | Phase 2 | 52 |
| Pirtobrutinib | Eli Lilly | Phase 2 | 52 |
| Ibrutinib + LY3214996 | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Acalabrutinib | Eli Lilly | Phase 2 | 52 |
| LYR-210 | Lyra Therapeutics | Phase 2 | 44 |
| LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2) | Lyra Therapeutics | Phase 2 | 44 |
| 480 Mometasone Furoate Sinus Drug Depot | Lyra Therapeutics | Phase 1 | 25 |
| LYR-210 + Sham procedure control | Lyra Therapeutics | Phase 3 | 69 |